CHF-1301 was launched as an injection in Italy for the treatment of
patients with Parkinson's disease, particularly those with complications in their
clinical responses. CHF-1301 is the methyl ester of L-Dopa (levodopa), the
immediate precursor of dopamine. Thus, this prodrug is more soluble in water at
physiological pH, better absorbed and slowly transformed into levodopa in vivo;
it consequently improves the duration of action and prevents the rapid
fluctuations in response or involontary movements (dyskinesia) observed during chronic treatment with levodopa. In patients with a delayed effect of levodopa
(on-phenomenon) or a severe resistance to L-Dopa (off-phenomenon), CHF-
1301 significantly improves the onset and the stability of the'response.
